The CMM Annual Sir Anthony Epstein Lecture 2017
1 December 2017
The School of Cellular and Molecular Medicine present their Annual Sir Anthony Epstein Lecture for 2017 with Professor Steve Jackson FRS FMedSci.
The Sir Anthony Epstein lecture was inaugurated at the University of Bristol in 2009 to recognise the achievements of outstanding scientists in the fields of cancer biology, infection and immunology. It celebrates the achievements of Sir Anthony Epstein who was Professor of Pathology at the University of Bristol (1968-85) and one of the discoverers of the Epstein-Barr virus.
This year we have invited Professor Steve Jackson FRS FMedSci from the Gurdon Institute, University of Cambridge to present this special lecture. The title of his talk is 'Cellular responses to DNA damage: translating mechanistic insights into precision cancer medicines', and will be hosted by Dr Abderrahmane Kaidi. He said of Professor Jackson's visit, "We are very honoured and excited to have Steve deliver the Annual Sir Anthony Epstein Lecture. Steve is internationally recognised for his fundamental research into DNA repair and for the successful application of knowledge of that process in the development of new cancer drugs".
Professor Steve Jackson FRS FMedSci is University of Cambridge and Cancer Research UK Professor of Biology, and Head of Cancer Research UK Laboratories at the Gurdon Institute. In his research publications, he has identified many key principles by which cells respond to and repair DNA damage. He identified many DNA repair proteins, established how they function and helped define how their dysfunction yields cancer and other age-related diseases. Professor Jackson has received various prizes, including the 2015 Gagna and van Heck Prize for Medicine, the 2016 King Faisal International Prize for Science, 2016 AH. Heineken Prize for Medicine, and the 2017 Genome Stability Network Medal.
To translate his academic work towards patient benefit, in 1997 he founded the drug-discovery company KuDOSPharmaceuticals Ltd., then served as part-time Chief Scientific Officer (CSO) until and after its acquisition by AstraZeneca. Several KuDOS-generated drugs are currently in clinical trials, with the most advanced, the PARP inhibitor olaparib/LynparzaTM, now being a marketed anti-cancer drug for certain ovarian cancers in over 40 countries. In 2010, he founded Mission Therapeutics Ltd. (Babraham, Cambridge) to exploit recent advances in protein ubiquitylation and deubiquitylation to derive new medicines, and serves as its part-time CSO. Professor Jackson's academic laboratory is currently further defining mechanisms of DNA repair and associated processes, with a view to identifying new therapeutic opportunities for cancer as well as various other genetic diseases.
The Annual Sir Anthony Epstein lecture is on Tuesday 5 December 2017 at 5 pm in lecture theatre E29 in the Biomedical Sciences Building and will be followed by a drinks reception for all those attending. The lecture is free to attend, with all staff, students and members of the public welcome to come along. Please email email@example.com to confirm your attendance.